CAPRIVI: Community Acquired Pneumonia: Treatment With Avelox® in Hospitalized Patients
NCT ID: NCT00987792
Last Updated: 2015-08-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2595 participants
OBSERVATIONAL
2009-09-30
2012-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
As this is a non-interventional observational study, routine clinical practice is observed. The application of medications follows the normal routines and is decided by the treating physician under recognition of the package insert.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Proof the Clinical and Bacteriological Non-inferiority of Ampicillin/Amoxicillin Versus Moxifloxacin in Hospitalized Patients With Non-severe Community-acquired Pneumonia
NCT00887276
Study to Evaluate the Efficacy and Safety of Oral Administration With Nemonoxacin and Levofloxacin in Patients With CAP
NCT01529476
A Molecular Toolkit for the Microbial Investigation of Severe Community Acquired Pneumonia
NCT02963142
Customized Antibiotic Treatment Duration Among Hospitalized Patients With Moderately Severe Community-Acquired Pneumonia
NCT05903352
Study to Demonstrate the Clinical Efficacy of Levofloxacin in the Treatment of Pneumonia
NCT00253955
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Moxifloxacin (Avelox, BAY12-8039)
Hospitalized patients receiving Avelox according to local drug information
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Moxifloxacin (Avelox, BAY12-8039)
Hospitalized patients receiving Avelox according to local drug information
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Many Locations, , Croatia
Many Locations, , France
Many Locations, , Hungary
Many Locations, , Jordan
Many Locations, , Kazakhstan
Many Locations, , Lebanon
Many Locations, , Moldova
Many Locations, , North Macedonia
Many Locations, , Romania
Many Locations, , Russia
Many Locations, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kuzman I, Bezlepko A, Kondova Topuzovska I, Rokusz L, Iudina L, Marschall HP, Petri T. Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI). BMC Pulm Med. 2014 Jun 30;14:105. doi: 10.1186/1471-2466-14-105.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AX0801
Identifier Type: OTHER
Identifier Source: secondary_id
14522
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.